title: Increasing doses of purified influenza virus hemagglutinin and subvirion vaccines enhance antibody responses in the elderly.
abstract: The reactogenicities and immunogenicities of two influenza virus vaccines were compared in a placebo-controlled clinical trial among healthy ambulatory persons > or = 65 years old (mean age, 72 years). Volunteers were assigned randomly to receive 15-, 45-, or 135-micrograms doses of monovalent influenza A/Taiwan (H1N1) hemagglutinin (HA) or subvirion (SV) vaccine intramuscularly or a placebo. Increasing doses of SV vaccine were associated with a higher rate of injection site discomfort (P < 0.05; chi-square test for linear trend), but all doses of both vaccines were well tolerated. Increasing the dose of the HA or the SV vaccine resulted in increasingly higher postimmunization levels of serum hemagglutination inhibition and neutralizing antibody levels (P < 0.001; multiple linear regression). Mean serum antibody titers at 1 month increased two- to threefold with a ninefold increase in dose; the frequencies of fourfold or greater rises in titer likewise increased. An increase in the dose of the HA or the SV vaccine also resulted in increased frequencies of rises in immunoglobulin A or G antibody titers in nasal wash specimens. The frequencies increased approximately twofold for each vaccine with a ninefold increase in the dose. These data suggest that increasing the HA vaccine dose is a promising approach to the development of improved influenza virus vaccines for use in elderly people.
authors.affiliation: Department of Microbiology and Immunology, Baylor College of Medicine Houston, Texas 77030, USA.
authors.forename: W A
authors.initials: WA
authors.lastname: Keitel
authors.forename: T R
authors.initials: TR
authors.lastname: Cate
authors.forename: R L
authors.initials: RL
authors.lastname: Atmar
authors.forename: C S
authors.initials: CS
authors.lastname: Turner
authors.forename: D
authors.initials: D
authors.lastname: Nino
authors.forename: C M
authors.initials: CM
authors.lastname: Dukes
authors.forename: H R
authors.initials: HR
authors.lastname: Six
authors.forename: R B
authors.initials: RB
authors.lastname: Couch
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000914:Antibodies, Viral / Q000096:biosynthesis* / Q000276:immunology*; D004306:Dose-Response Relationship, Immunologic; D005260:Female; D019267:Hemagglutinin Glycoproteins, Influenza Virus / Q000276:immunology; D006389:Hemagglutinins, Viral / Q000276:immunology*; D006801:Humans; D007252:Influenza Vaccines / Q000145:classification* / Q000276:immunology*; D008297:Male; D014613:Vaccines, Attenuated / Q000276:immunology
chemical_list: D000914:Antibodies, Viral; D019267:Hemagglutinin Glycoproteins, Influenza Virus; D006389:Hemagglutinins, Viral; D007252:Influenza Vaccines; D014613:Vaccines, Attenuated